Targeted Anti-Interleukin-6 Monoclonal Antibody Therapy for Cancer: A Review of the Rationale and Clinical Evidence

Clinical Cancer Research

Volumn 9, Issue 13, 2003, Pages 4653-4665

  Trikha, Mohit ^a   Corringham, Robert ^a   Klein, Bernard ^b   Rossi, Jean François ^b  

^a CENTOCOR INC   (United States)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BE 8; CARBOPLATIN; CNTO 328; CORTICOSTEROID; DEXAMETHASONE; ESTROGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6 DIPHTHERIA TOXIN FUSION PROTEIN; INTERLEUKIN 6 MONOCLONAL ANTIBODY; INTERLEUKIN 6 PSEUDOMONAS EXOTOXIN FUSION PROTEIN; INTERLEUKIN 6 RECEPTOR; MELPHALAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BE 4; MONOCLONAL ANTIBODY BE 8; MONOCLONAL ANTIBODY CCLB8; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 6; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTHRALGIA; ATAXIA; CACHEXIA; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL TRIAL; CONFUSION; DOSE CALCULATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FEVER; FLU LIKE SYNDROME; GENETIC TRANSCRIPTION; HEART ATRIUM FIBRILLATION; HEMATOPOIESIS; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; INFLAMMATION; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKOCYTOSIS; LYMPHOPROLIFERATIVE DISEASE; MELANOMA; MULTIPLE MYELOMA; NEUROTOXICITY; NEUTROPENIA; PARAPLEGIA; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING; REVIEW; SEPSIS; SIDE EFFECT; SLURRED SPEECH; STEM CELL; THROMBOCYTOPENIA; THROMBOCYTOSIS; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; VISUAL IMPAIRMENT; VOMITING;

ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-6; KIDNEY NEOPLASMS; LYMPHOMA, B-CELL; MULTIPLE MYELOMA; NEOPLASMS;

EID: 0142250392     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (129)

1. Barton, B. E. IL-6: insights into novel biological activities. Clin. Immunol. Immunolpathol., 85: 16-20, 1997.
2. Kishimoto, T., Taga, T., Yamasaki, K., Matsuda, T., Tang, B., Muraguchi, A., Horii, Y., Suematsu, S., Hirata, Y., and Yawata, H. Normal and abnormal regulation of human B cell differentiation by a new cytokine, BSF2/IL-6. Adv. Exp. Med. Biol., 254: 135-143, 1989.
3. Jones, S. A., Horiuchi, S., Topley, N., Yamamoto, N., and Fuller, G. M. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J., 15: 43-58, 2001.
4. Kishimoto, T., Tanaka, T., Yoshida, K., Akira, S., and Taga, T. Cytokine signal transduction through a homo- or heterodimer of gp130. Ann. N. Y. Acad. Sci., 766: 224-234, 1995.
5. Jourdan, M., Bataille, R., Seguin, J., Zhang, X. G., Chaptal, P. A., and Klein, B. Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. Arthritis Rheum., 33: 398-402, 1990.
6. Jego, G., Bataille, R., and Pellat-Deceunynck, C. Interleukin-6 is a growth factor for nonmalignant human plasmablasts. Blood, 97: 1817-1822, 2001.
7. Klein, B., Zhang, X. G., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M., and Bataille, R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood, 73: 517-526, 1989.
8. Keller, E. T., Wanagat, J., and Ershler, W. B. Molecular and cellular biology of interleukin-6 and its receptor. Front. Biosci., 1: d340-d357, 1996.
9. Simpson, R. J., Hammacher, A., Smith, D. K., Matthews, J. M., and Ward, L. D. Interleukin-6: structure-function relationships. Protein Sci., 6: 929-955, 1997.
10. Tupitsyn, N., Kadagidze, Z., Gaillard, J-P., Sholokhova, E., Andreeva, L., Liautard, J., Duperray, C., Klein, B., and Brochier, J. Functional interaction of the gp80 and gp130 IL-6 receptors in human B cell malignancies. Clin. Lab. Haematol., 20: 345-352, 1998.
11. Grant, S. L., Hammacher, A., Douglas, A. M., Goss, G. A., Mansfield, R. K., Heath, J. K., and Begley, C. G. An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells. Oncogene, 21: 460-474, 2002.
12. Badache, A., and Hynes, N. E. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res., 61: 383-391, 2001.
13. Wang, Y. D., De Vos, J., Jourdan, M., Couderc, G., Lu, Z. Y., Rossi, J. F., and Klein, B. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells. Oncogene, 21: 2584-2592, 2002.
14. Kishimoto, T., Akira, S., and Taga, T. Interleukin-6 and its receptor: a paradigm for cytokines. Science (Wash. DC), 258: 593-597, 1992.
15. Ward. L. D., Howlett, G. J., Discolo, G., Yasukawa, K., Hammacher, A., Moritz, R. L., and Simpson, R. J. High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130. J. Biol. Chem., 269: 23286-23289, 1994.
16. Mullberg, J., Schooltink, H., Stoyan, T., Gunther, M., Graeve, L., Buse, G., Mackiewicz, A., Heinrich, P. C., and Rose-John, S. The soluble interleukin-6 receptor is generated by shedding. Eur. J. Immunol., 23: 473-480, 1993.
17. Horiuchi, S., Koyanagi, Y., Zhou, Y., Miyamoto, H., Yamamoto, M., and Yamamoto, N. Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur. J. Immunol., 24: 1945-1948, 1994.
18. Diamant, M., Rieneck, K., Mechti, N., Zhang, X. G., Svenson, M., Bendtzen, K., and Klein, B. Cloning and expression of an alternatively spliced mRNA encoding a soluble form of the human interleukin-6 signal transducer gp130. FEBS Lett., 412: 379-384, 1997.
19. Wolfsberg, T. G., and White, J. M. ADAMs in fertilization and development. Dev. Biol., 180: 389-401, 1996.
20. Kollet, O., Aviram, R., Chebath, J., ben-Hur, H., Nagler, A., Shultz, L., Revel, M., and Lapidot, T. The soluble interleukin-6 (IL-6) receptor/ IL-6 fusion protein enhances in vitro maintenance and proliferation of human CD34+CD38-/low cells capable of repopulating severe combined immunodeficiency mice. Blood, 94: 923-931, 1999.
21. Gupta, P., Blazar, B. R., Gupta, K., and Verfaillie, C. M. Human CD34+ bone marrow cells regulate stromal production of interleukin-6 and granulocyte colony-stimulating factor and increase the colony-stimulating activity of stroma. Blood, 91: 3724-3733, 1998.
22. Omura, H., Kawatani, T., Tajima, F., Ishiga, K., Kawasaki, H., and Nariba, E. Serum soluble IL-6 receptor levels during the mobilization of stem cells to peripheral blood. Leuk. Lymphoma, 43: 623-630, 2002.
23. Tsuruda, T., Jougasaki, M., Boerrigter, G., Huntley, B. K., Chen, H. H., D'Assoro, A. B., Lee, S. C., Larsen, A. M., Cataliotti, A., and Burnett, J. C., Jr. Cardiotrophin-1 stimulation of cardiac fibroblast growth: roles for glycoprotein 130/leukemia inhibitory factor receptor and the endothelin type A receptor. Circ. Res., 90: 128-134, 2002.
24. Viswanathan, S., Benatar, T., Rose-John, S., Lauffenburger, D. A., and Zandstra, P. W. Ligand/receptor signaling threshold (LIST) model accounts for gp130-mediated embryonic stem cell self-renewal responses to LIF and HIL-6. Stem Cells, 20: 119-138, 2002.
25. Edoff. K., and Jerregard, H. Effects of IL-1b, IL-6 or LIF on rat sensory neurons co-cultured with fibroblast-like cells. J. Neurosci. Res., 67: 255-263, 2002.
26. Kurihara, N., Bertolini, D., Suda, T., Akiyama, Y., and Roodman, G. D. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J. Immunol., 144: 4226-4230, 1990.
27. Malaval, L., Gupta, A. K., Liu, F., Delmas, P. D., and Aubin, J. E. LIF, but not IL-6, regulates osteoprogenitor differentiation in rat calvaria cell cultures: modulation by dexamethasone. J. Bone Miner. Res., 13: 175-184, 1998.
28. Benoy, I., Salgado, R., Colpaert, C., Weytjens, R., Vermeulen, P. B., and Dirix, L. Y. Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin. Breast Cancer, 2: 311-315, 2002.
29. Zhang, G-J., and Adachi, I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res., 19: 1427-1432, 1999.
30. Yokoe, T., Iino, Y., Takei, H., Horiguchi, J., Koibuchi, Y., Maemura, M., Ohwada, S., and Morishita, Y. Changes of cytokines and thyroid function in patients with recurrent breast cancer. Anticancer Res., 17: 695-699, 1997.
31. Yamashita, J-I., and Ogawa, M. Medroxyprogesterone acetate and cancer cachexia: interleukin-6 involvement. Breast Cancer, 7: 130-135, 2000.
32. Mantovani, G., Maccio, A., Lai, P., Massa, E., Ghiani, M., and Santona, M. C. Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms. Crit. Rev. Oncog., 9: 99-106, 1998.
33. De Vita, F., Romano, C., Orditura, M., Galizia, G., Martinelli, E., Lieto, E., and Catalano, G. Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J. Interferon Cytokine Res., 21: 45-52, 2001.
34. Kinoshita, T., Ito, H., and Miki, C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer (Phila.), 85: 2526-2531, 1999.
35. Goydos, J. S., Brumfield, A. M., Frezza, E., Booth, A., Lotze, M. T., and Carty, S. E. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann. Surg., 227: 398-404, 1998.
36. Jablonska, E., Piotrowski, L., and Grabowska, Z. Serum levels of IL-1b, IL-6, TNF-α, sTNF-RI and CRP in patients with oral cavity cancer. Pathol. Oncol. Res., 3: 126-129, 1997.
37. Wu, C. W., Wang, S. R., Chao, M. F., Wu, T. C., Lui, W. Y., P'eng, F. K., and Chi, C. W. Serum interleukin-6 levels reflect disease status of gastric cancer. Am. J. Gastroenterol., 91: 1417-1422, 1996.
38. Robak, T., Wierzbowska, A., Blasinska-Morawiec, M., Korycka, A., and Blonski, J. Z. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission. Mediat. Inflamm., 8: 277-286, 1999.
39. Fayad, L., Cabanillas, F., Talpaz, M., McLaughlin, P., and Kurzrock, R. High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. Leuk. Lymphoma, 30: 563-571, 1998.
40. Seymour, J. F., Talpaz, M., Hagemeister, F. B., Cabanillas, F., and Kurzrock, R. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease. Am. J. Med., 102: 21-28, 1997.
41. Preti, H. A., Cabanillas, F., Talpaz, M., Tucker, S. L., Seymour, J. F., and Kurzrock, R. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann. Intern. Med., 127: 186-194, 1997.
42. Alexandrakis, M. G., Coulocheri, S. A., Bouros, D., Mandalaki, K., Karkavitsas, N., and Eliopoulos, G. D. Evaluation of inflammatory cytokines in malignant and benign pleural effusions. Oncol. Rep., 7: 1327-1332, 2000.
43. Dowlati, A., Levitan, N., and Remick, S. C. Evaluation of interleukin-6 in broncheoalveolar lavage fluid and serum of patients with lung cancer. J. Lab. Clin. Med., 134: 405-409, 1999.
44. Martin, F., Santolaria, F., Batista, N., Milena, A., Gonzalez-Reimers, E., Brito, M. J., and Orama, J. Cytokine levels (IL-6 and IFN-γ), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine, 11: 80-86, 1999.
45. De Vita, F., Orditura, M., Auriemma, A., Infusino, S., Roscigno, A., Catalano, G. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol. Rep., 5: 649-652, 1998.
46. Nakano, T., Chahinian, A. P., Shinjo, M., Tonomura, A., Miyake, M., Togawa, N., Ninomiya, K., and Higashino, K. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br. J. Cancer, 77: 907-912, 1998.
47. Moretti, S., Chiarugi, A., Semplici, F., Salvi, A., De Giorgio, V., Fabbri, P., and Mazzoli, S. Serum imbalance of cytokines in melanoma patients. Melanoma Res., 11: 395-399, 2001.
48. Mouawad, R., Benhammouda, A., Rixe, O., Antoine, E. C., Borel, C., Weil, M., Khayat, D., and Soubrane, C. Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin. Cancer Res., 2: 1405-1409, 1996.
49. Frassanito, M. A., Cusmai, A., and Dammacco, F. Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin. Exp. Immunol., 125: 190-197, 2001.
50. Urbanska-Rys, H., Wiersbowska, A., Stepien, H., and Robak, T. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma. Eur. Cytokine Netw., 11: 443-451, 2000.
51. Wierzbowska, A., Urbanska-Rys, H., and Robak, T. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma. Br. J. Haematol., 105: 412-419, 1999.
52. Pulkki, K., Pelliniemi, T-T., Rajamaki, A., Tienhaara, A., Laakso, M., and Lahtinen, R. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Br. J. Haematol., 92: 370-374, 1996.
53. Tempfer, C., Zeisler, H., Sliutz, G., Haeusler, G., Hanzal, E., and Kainz, C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol. Oncol., 66: 27-30, 1997.
54. Okada, S., Okusaka, T., Ishii, H., Kyogoku, A., Yoshimori, M., Kajimura, N., Yamaguchi, K., and Kakizoe, T. Elevated serum interleukin-6 levels in patients with pancreatic cancer. Jpn. J. Clin. Oncol., 28: 12-15, 1998.
55. Nakashima, J., Tachibana, M., Horiguchi, Y., Oya, M., Ohigashi, T., Asakura, H., and Murai, M. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin. Cancer Res., 6: 2702-2706, 2000.
56. Wise, G. J., Marella, V. K., Talluri, G., and Shirazian, D. Cytokine variations in patients with hormone treated prostate cancer. J. Urol., 164: 722-725, 2000.
57. Adler, H. L., McCurdy, M. A., Kattan, M. W., Timme, T. L., Scardino, P. T., and Thompson, T. C. Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J. Urol., 161: 182-187, 1999.
58. Drachenberg, D. E., Elgamal, A-A. A., Rowbotham, R., Peterson, M., and Murphy, G. P. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate, 41: 127-133, 1999.
59. Akimoto, S., Okumura, A., and Fuse. H. Relationship between serum levels of interleukin-6, tumor necrosis factor-α and bone turnover markers in prostate cancer patients. Endocr. J., 45: 183-189, 1998.
60. Kallio, J. P., Tammela, T. L. J., Marttinen, A. T., and Kellokumpu-Lehtinen, P-L. I. Soluble immunological parameters and early prognosis of renal cell cancer patients. J. Exp. Clin. Cancer Res., 20: 523-528, 2001.
61. Hayakawa, M., Nakajima, F., Tsuji, A., Asano, T., Hatano, T., and Nakamura, H. Cytokine levels in cystic renal masses associated with renal cell carcinoma. J. Urol., 159: 1459-1464, 1998.
62. Walther, M. M., Johnson, B., Culley, D., Shah, R., Weber, J., Venson, D., Yang, J. C., Linehan, W. M., and Rosenberg, S. A. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlate with paraneoplastic syndromes but not patient survival. J. Urol., 159: 718-722, 1998.
63. Blay, J-Y., Rossi, J-F., Wijdenes, J., Menetrier-Caux, C., Schemann, S., Negrier, S., Philip, T., and Favrot, M. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int. J. Cancer, 72: 424-430, 1997.
64. Costes, V., Liautard, J., Picot, M-C., Robert, M., Lequeux, N., Brochier, J., Baldet, P., and Rossi, J-F. Expression of the interleukin 6 receptor in primary renal cell carcinoma. J. Clin. Pathol., 50: 835-840, 1997.
65. Ljungberg, B., Grankvist, K., and Rasmuson, T. Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur. J. Cancer, 33: 1794-1798, 1997.
66. Smith, P. C., and Keller, E. T. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate, 48: 47-53, 2001.
67. Aaronson, S. A. Growth factors and cancer. Science (Wash. DC), 254: 1146-1153, 1991.
68. Miki, S., Iwano, M., Miki, Y., Yamamoto, M., Tang, B., Yokokawa, K., Sonoda, T., Hirano, T., and Kishimoto, T. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett., 250: 607-610, 1989.
69. Dedhar, S., Gaboury, L., Galloway, P., and Eaves, C. Human granulocyte-macrophage colony-stimulating factor is a growth factor active on a variety of cell types of nonhemopoietic origin. Proc. Natl. Acad. Sci. USA, 85: 9253-9257, 1988.
70. Novick, D., Shulman, L. M., Chen, L., and Revel, M. Enhancement of interleukin 6 cytostatic effect on human breast carcinoma cells by soluble IL-6 receptor from urine and reversion by monoclonal antibody. Cytokine, 4: 6-11, 1992.
71. , Tate, J., Finke, J., Kottke-Marchant, K., Rybicki, L. A., and Bukowski, R. M. Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal-cell carcinoma: clinical and laboratory effects. Ann. Oncol., 12: 655-659, 2001.
72. Sosman, J. A., Aronson, F. R., Sznol, M., Atkins, M. B., Dutcher, J. P., Weiss, G. R., Isaacs, R. E., Margolin, K. A., Fisher, R. I., Ernest, M. L., Mier, J., Oleksowicz, L., Eckhardt, J. R., Levitt, D., and Doroshow, J. H. Concurrent Phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity. Clin. Cancer Res., 3: 39-46, 1997.
73. Lu, C., Vickers, M. F., and Kerbel, R. S. Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc. Natl. Acad. Sci. USA, 89: 9215-9219, 1992.
74. Lu, C., and Kerbel, R. S. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J. Cell Biol. 120: 1281-1288, 1993.
75. Silvani, A., Ferrari, G., Paonessa, G., Toniatti, C., Parmiani, G., and Colombo, M. P. Down-regulation of interleukin 6 receptor α chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin M. Cancer Res. 55: 2200-2205, 1995.
76. O'Brien, S., del Giglio, A., and Keating, M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood, 85: 307-318, 1995.
77. Rozman, C., and Monsterrat, E. Chronic lymphocytic leukemia. N. Engl. J. Med., 333: 1052-1057, 1995.
78. Emilie, D., Leger-Ravet, M-B., Devergne, O., Raphael, M., Peuchmaur, M., Coumbaras, J., Crevon, M-C., and Galanaud, P. Intratumoral production of IL-6 in B cell chronic lymphocytic leukemia and B lymphomas. Leuk. Lymphoma, 11: 411-417, 1993.
79. Van-Kooten, C., Rensink, I., Aarden, L., and van Oers, R. Effect of IL-4 and IL-6 on the proliferation and differentiation of B-chronic lymphocytic leukemia cells. Leukemia (Baltimore), 7: 618-624, 1993.
80. Aderka, D., Maor, Y., Novick, D., Engelmann, H., Kahn, Y., Levo, Y., Wallach, D., and Revel, M. Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-α or -β. Blood, 81: 2076-2084, 1993.
81. Lai, R., O'Brien, S., Maushouri, T., Rogers, A., Kantarjian, H., Keating, M., and Albitar, M. Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Cancer (Phila.), 95: 1071-1075, 2002.
82. Hulkkonen, J., Vilpo, J., Vilpo, L., Koski, T., and Hurme, M. Interleukin-β, interleukin-I receptor antagonist and interleukin-6 plasma levels and cytokine gene polymorphisms in chronic lymphocytic leukemia: correlation with prognostic parameters. Haematologica, 85: 600-606, 2000.
83. Moreno, A., Villar, M. L., Camara, C., Luque, R., Cespon, C., Gonzalez-Porque, P., Roy, G., Lopez-Jimenez, J., Bootello, A., and Santiago, E. R. Interleukin-6 dimers produced by endothelial cells inhibit apoptosis of B-chronic lymphocytic leukemia cells. Blood, 97: 242-249, 2001.
84. Gause, A., Schloz, R., Klein, S., Jung, W., Diehl, V., Tesch, H., Hasenclever, D., and Pfreundschuh, M. Increased levels of circulating interleukin-6 in patients with Hodgkin's disease. Hematol. Oncol., 9: 307-313, 1991.
85. Kurzrock, R., Redman, J., Cabanillas, F., Jones, D., Rothberg, J., and Talpaz, M. Serum interleukin-6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res., 53: 2118-2122, 1993.
86. Stasi, R., Conforti, M., Del Poeta, G., Simone, M. D., Coppetelli, U., Tribalto, M., Cantonetti, M., Perrotti, A., Venditti, A., and Papa, G. Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas. Haematologica, 77: 518-521, 1992.
87. Yamamura, M., Yamada, Y., Momita, S., Kamihira, S., and Tomonaga, M. Circulating interleukin-6 levels are elevated in adult-T-cell leukemia/lymphoma patients and correlate with adverse clinical features and survival. Br. J. Haematol., 100: 129-134, 1998.
88. Fayad, L., Keating, M. J., Reuben, J. M., O'Brien, S., Lee. B-N., Lemer, and Kurzrock R. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood, 97: 256-263, 2001.
89. Klein, B., Zhang, X-G., Lu, Z-Y., and Bataille, R. Interleukin-6 in human multiple myeloma. Blood, 85: 863-872, 1995.
90. Costes, V., Portier, M., Lu, Z-Y., Rossi, J-F., Bataille, R., and Klein, B. Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production. Br. J. Haematol., 103: 1152-1160, 1998.
91. Hinson, R. M., Williams, J. A., and Shacter, E. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc. Natl. Acad. Sci. USA, 93: 4885-4890, 1996.
92. Zhang, X. G., Gu, J. J., Lu, Z. Y., Yasukawa, K., Yancopoulos, G. D., Turner, K., Shoyab, M., Taga, T., Kishimoto, T., and Bataille, R., Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J. Exp. Med., 179: 1337-1342, 1994.
93. Klein, B., Lu, Z. Y., Gu, Z. J., Costes, V., Jourdan, M., and Rossi, J-F. Interleukin-10 and gp130 cytokines in human multiple myeloma. Leuk. Lymphoma, 34: 63-70, 1999.
94. Gu, Z-J., Costes, V., Lu, Z. Y., Zhang, X. G., Pitard, V., Moreau, J. F., and Bataille, R. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood, 88: 3972-3986, 1996.
95. Bataille, R., Jourdan, M., Zhang, X. G., and Klein, B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J. Clin. Investig., 84: 2008-2011, 1989.
96. Gaillard, J-P., Bataille, R., Brailly, H., Zuber, C., Yasukawa, K., Attal, M., Maruo, N., Taga, T., Kishimoto, T., and Klein, B. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur. J. Immunol., 23: 820-824, 1993.
97. Bataille, R., Boccadoro, M., Klein, B., Durie, B., and Pileri, A. C-reactive protein and β2 microglobulin produce a simple and powerful myeloma staging system. Blood, 80: 733-737, 1992.
98. Jourdan, M., De Vos, J., Mechti, N., and Klein, B. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-α and insulin-like growth factor 1. Cell Death Differ., 7: 1244-1252, 2000.
99. L is an essential survival protein of human myeloma cells. Blood, 100: 194-199, 2002.
100. Takenawa, J., Kaneko, Y., Fukumoto, M., Fukatsu, A., Hirano, T., Fukuyama, H., Nakayama, H., Fujita, J., and Yoshida, O. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J. Natl. Cancer Inst. (Bethesda), 83: 1668-1672, 1991.
101. Haitel, A., Wiener, H. G., Baethge, U., Marberger, M., and Susani, M. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin. Cancer Res., 6: 1840-1844, 2000.
102. Oda, H., Nakatsuru, Y., and Ishikawa, T. Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas. Cancer Res., 55: 658-662, 1995.
103. Angelo, L. S., Talpaz, M., and Kurzrock, R. Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. Cancer Res., 62: 932-940, 2002.
104. Uhlman, D. L., Nguyen, P. L., Manivel, J. C., Aeppli, D., Resnick, J. M., Fraley, E. E., Zhang, G., and Niehans, G. A. Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J. Natl. Cancer Inst. (Bethesda), 86: 1470-1475, 1994.
105. Reiter, R. E., Anglard, P., Liu, S., Gnarra, J. R., and Linehan, W. M. Chromosome 17p deletions and p53 mutations in renal cell carcinoma. Cancer Res., 53: 3092-3097, 1993.
106. Yoshida, N., Ikemoto, S., Narita, K., Sugimura, K., Wada, S., and Yasumoto, R. Interleukin-6, tumour necrosis factor α and interleukin-1β in patients with renal cell carcinoma. Br. J. Cancer, 86: 1396-1400, 2002.
107. Papac, R. J., and Poo-Hwu, W. J. Renal cell carcinoma: a paradigm of lanthanic disease. Am. J. Clin. Oncol., 22: 223-231, 1999.
108. Weissglas, M., Schamhart, D., Lowik, C., Papapoulos, S., Vos, P., and Kurth, K-H. Hypercalcemia and cosecretion of interleukin-6 and parathyroid hormone related peptide by a human renal cell carcinoma implanted into nude mice. J. Urol., 153, 854-857, 1995.
109. Musselman, D. L., Miller, A. H., Porter, M. R., Manatunga, A., Gao, F., Penna, S., Pearce, B. D., Landry, J., Glover, S., McDaniel, J. S., and Nemeroff, C. B. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am. J. Psychiatry, 158: 1252-1257, 2001.
110. Loprinzi, C. L., Ellison, N. M., Goldberg, R. M., Michalak. J. C., and Burch, P. A. Alleviation of cancer anorexia and cachexia: studies of the Mayo Clinic and the North Central Cancer Treatment Group. Semin. Oncol., 17: 8-12, 1990.
111. Tisdale, M. J. Biology of cachexia. J. Natl. Cancer Inst. (Bethesda), 89: 1763-1773, 1997.
112. Mizutani, Y., Bonavida, B., Koishihara, Y., Akamatsu, K., Ohsugi, Y., and Yoshida, O. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res., 55: 590-596, 1995.
113. Lauta, V. M. Interleukin-6 and the network of several cytokines in multiple myeloma: an overview of clinical and experimental data. Cytokine, 16: 79-86, 2001.
114. Brochier, J., Gaillard, J. P., and Klein, B. Membrane and soluble IL-6 receptors: tools of diagnosis and targets for immune intervention. Curr. Trends Immunol., 1: 105-121, 1998.
115. Klein, B., Wijdenes, J., Zhang, X-G., Jourdan, M., Boiron, J. M., Brochier, J., Liautard, J., Merlin, M., Clement, C., and Morel-Fournier, B. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood, 78: 1198-1204, 1991.
116. Emilie, D., Wijdenes, J., Gisselbrech, C., Jarrouse, B., Billaud, E., Blay, J-Y., Gabarre, J., Gaillard, J. P., Brochier, J., and Raphael, M. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms. Blood, 84: 2472-2479, 1994.
117. Bataille, R., Barlogie, B., Lu, Z. Y., Rossi, J-F., Lavabre-Bertrand, T., Beck, T., Wijdenes, J., Brochier, J., and Klein, B. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood, 86: 685-691, 1995.
118. van Zaanen, H. C. T., Koopmans, R. P., Aarden, L. A., Rensink, H. J., Stouthard, J. M., Warnaar, S. O., Lokhorst, H. M., and van Oers, M. H. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J. Clin. Investig., 98: 1441-1448, 1996.
119. van Zaanen, H. C. T., Lokhorst, H. M., Aarden, L. A., Rensink, H. J., Wamaar, S. O., van der Lelie, J., and van Oers, M. H. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br. J. Haematol., 102: 783-790, 1998.
120. Moreau, P., Harousseau, J-L., Wijdenes, J., Morineau, N., Milpied, N., and Bataille, R. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br. J. Haematol., 109: 661-664, 2000.
121. Haddad, E., Paczesny, S., Leblond, V., Seigneurin, J. M., Stern, M., Achkar. A., Bauwens, M., Delwail, V., Debray, D., Duvoux, C., Hubert, P., de Ligny, B. H., Wijdenes, J., Durandy, A., and Fischer, A. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood, 97: 1590-1597, 2001.
122. Lu, Z-Y., Brailly, H., Rossi, J-F., Wijdenes, J., Bataille, R., and Klein, B. Overall interleukin-6 production exceeds 7 mg/day in multiple myeloma complicated by sepsis. Cytokine, 5: 578-582, 1993.
123. Lu, Z. Y., Brailly, H., Wijdenes, J., Bataille, R., Rossi, J-F., and Klein, B. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood, 86: 3123-3131, 1995.
124. Legouffe, E., Liautard, J., Gaillard, J. P., Rossi, J-F., Wijdenes, J., Bataille, R., Klein, B., and Brochier, J. Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6. Clin. Exp. Immunol., 98: 323-329, 1994.
125. Durie, B. G. M., and Salmon, S. E. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer (Phila.), 36: 842-854, 1975.
126. Nishimoto, N., Sasai, M., Shima, Y., Nakagawa, M., Matsumoto, T., Shirai, T., Kishimoto, T., and Yoshizaki, K. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood, 95: 56-61, 2000.
127. Yoshizaki, K., Nishimoto, N., Mihara, M., and Kishimoto, T. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin. Immunopathol., 20: 247-259, 1998.
128. Klein, B., and Brailly, H. Cytokine-binding proteins: stimulating antagonists. Immunol. Today, 16: 216-220, 1995.
129. Brochier, J., Liautard, J., Jacque, C., Gaillard, J. P., and Klein, B. Optimizing therapeutic strategies to inhibit circulating soluble target molecules with monoclonal antibodies: example of the soluble IL-6 receptors. Eur. J. Immunol., 31: 259-264, 2001.